Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 2Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × LY2940680 × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡